Drugs / Tisseel
Tisseel
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04664738 | Mar 2021 → Aug 2023 | — | Rion Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02584153 | Jan → Dec 2019 | — | Hobart Harris | Withdrawn | No outcome recorded |
| Phase 1 | NCT00155402 | Apr 2005 → Mar 2008 | corneal ulcer, pterygium | National Taiwan University Hospital | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05358977 | May 2022 → May 2023 | eyelid disorder, ptosis | University of Calgary | Unknown | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01613664 | Feb 2014 → May 2018 | morbid obesity | Centre Hospitalier Universitaire, Amiens | Completed | Missed primary |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT02953145 | Sep 2019 → Sep 2020 | cleft palate | University of Alberta | Withdrawn | No outcome recorded |
| Phase 4 | NCT00775034 | Jan 2010 → Oct 2014 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00324272 | Jan 2003 → Dec 2006 | melanoma, squamous cell carcinoma | Oxford University Hospitals NHS Trust | Completed | Missed primary |
| Phase not applicable3 trials | ||||||
| — | NCT05490940 | Mar 2023 → Dec 2025 | peripheral nerve lesion | Insel Gruppe AG, University Hospital Bern | Unknown | No outcome recorded |
| — | NCT00504582 | May 2002 → Apr 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00181974 | Mar 2000 → Feb 2007 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT06793748 Comparator | Jun → Nov 2025 overdue | chronic ulcer of skin | Rion Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06319287 Comparator | Feb 2024 → Apr 2025 | ulcer of lower limbs | Rion Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03276975 Comparator | Dec 2017 → Mar 2020 | cerebrospinal fluid leak | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02545153 Comparator | Jan 2009 → Jan 2016 | choledocholithiasis, infectious disease | Enköping Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03733639 Comparator | Jul 2020 → Jul 2021 | gastric cancer, intestinal perforation | Germans Trias i Pujol Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03310060 Comparator | Nov 2017 → Aug 2018 | — | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tisseel | “In the arm "Tisseel®" surgeon dispenses the product all over the anastomosis.” NCT03733639 ↗17“Tisseel applied externally to the dissected axillary area.” NCT00504582 ↗ “TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)” NCT02584153 ↗ |
| Known as | Fibrin Sealant | “Fibrin Sealant (Tisseel) used in the Experimental Arm.” NCT00324272 ↗ |
| Known as | TISSEEL VH SD Kit | “Fibrin Sealant (TISSEEL® VH SD Kit)” NCT06793748 ↗ |
| Known as | tissue fibrin glue | “tissue fibrin glue application (Tisseel)” NCT00155402 ↗ |
| Modality | Protein / enzyme biologic | “Fibrin sealant is produced from human fibrinogen and human thrombin from pooled plasma” NCT00181974 ↗ |
| Route | Other | “4 ml of Tisseel fibrin sealant were instilled into the wound” NCT00324272 ↗ |